OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press89410.17650/1818-8346-2024-19-1-14-20MULTIPLE MYELOMA. EXPERT COUNCIL DISCUSSIONМНОЖЕСТВЕННАЯ МИЕЛОМА. ОБСУЖДЕНИЕ ЭКСПЕРТНОГО СОВЕТАReview of the Expert Council “Multiple myeloma: the era of monoclonal antibodies in the treatment of patients with multiple myeloma”Обзор экспертного совета «Множественная миелома: эра моноклональных антител в терапии пациентов с множественной миеломой»AkhmedovM. I.АхмедовМ. И.
Russian Federation

Ахмедов Мобил Илгарович, к.м.н., доцент кафедры  онкологии и онкохирургии ФГБОУ ВО «Российский  университет медицины» Минздрава России, старший  научный сотрудник отделения высокодозной  химиотерапии и трансплантации костного мозга 

ZeynalovaP. A.ЗейналоваП. А.
Russian Federation

Зейналова Первин Айдыновна, д.м.н., профессор, заместитель директора онкологического центра, заведующая отделением онкогематологии Клинического госпиталя «Лапино 2» группы компаний «Мать и дитя», профессор кафедры онкологии

МНИОИ им. П.А. Герцена – филиала ФГБУ «НМИЦ радиологии» Минздрава РоссииФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)2701202419114202501202425012024https://oncohematology.abvpress.ru/ongm/article/view/894

.

.

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. NEJM. Available at: https://www.nejm.org/doi/ full/10.1056/nejmoa2024850 (accessed January 9, 2024).Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. NEJM. Available at: https://www.nejm.org/doi/full/10.1056/nejmoa2024850 (accessed January 9, 2024).Berdeja J.G., Madduri D., Usmani S.Z. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398(10297):314–24. DOI: 10.1016/S0140-6736(21)00933-8Cohen A.D., Mateos M.V., Cohen Y.C. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 2023;141(3): 219–30. DOI: 10.1182/blood.2022015526Munshi N.C., Avet-Loiseau H., Anderson K.C. et al. A large metaanalysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4(23):5988–99. DOI: 10.1182/bloodadvances.2020002827Moreau P., Dimopoulos M.A., Mikhael J. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397(10292):2361–71. DOI: 10.1016/S0140-6736(21)00592-4Davies F.E., Leleu X., Vogel P. et al. A meta-analysis of the efficacy of pomalidomide-based regimens for the treatment of relapsed/ refractory multiple myeloma after lenalidomide exposure. Clin Lymphoma Myeloma Leuk 2023;23(11):829–37.e1. DOI: 10.1016/j.clml.2023.07.010Yang B., Yu R., Chi X., Lu X. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One 2013;8(5):e64354. DOI: 10.1371/journal.pone.0064354Palumbo A., Chanan-Khan A., Weisel K. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375(8):754–66. DOI: 10.1056/NEJMoa1606038Dimopoulos M.A., Oriol A., Nahi H. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375(14):1319–31. DOI: 10.1056/NEJMoa1607751Тафалгин. Инструкция по применению, дозы, побочные действия, отзывы о препарате Тафалгин: раствор для подкожного введения, 4 мг/мл. Доступно по: https://www.rlsnet.ru/drugs/tafalgin-81734 (дата обращения 11.03.2023) Tafalgin. Instructions for use, doses, side effects, reviews of the drug Tafalgin: solution for subcutaneous administration, 4 mg/ml. Available at: https://www.rlsnet.ru/drugs/tafalgin-81734 (accessed March 11, 2023).Akhmedov M. Infectious complications in allogeneic hematopoietic cell transplant recipients: review of transplant-related risk factors and current state of prophylaxis. Clin Transplant 2021;35(2):e14172. DOI: 10.1111/ctr.14172Akhmedov M., Wais V., Sala E. et al. Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes. Transpl Infect Dis 2020;22(4):e13276. DOI: 10.1111/tid.13276Akhmedov M., Klyasova G., Kuzmina L. et al. Incidence, etiology, risk factors and outcomes of pre-engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation. Transpl Infect Dis 2022;24(3):e13842. DOI: 10.1111/tid.13842Akhmedov M., Klyasova G., Kuzmina L., Parovichnikova E. Recurrent bloodstream infections after allogeneic hematopoietic cell transplantation. Expert Rev Anti Infect Ther 2023;21(1):87–90. DOI: 10.1080/14787210.2023.2151440Akhmedov M., Klyasova G., Kuzmina L. et al. Post-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: risk factors and association with mortality. Infect Chemother 2023;55(2):204–13. DOI: 10.3947/ic.2022.0146Akhmedov M., Klyasova G., Kuzmina L. et al. Impact of fluoroquinolone administration and gut mucosal colonization on the risk of pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation. Leuk Lymphoma 2023;64(6):1102–11. DOI: 10.1080/10428194.2023.21975322022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, Oxford Academic. Available at: https://academic.oup.com/eurheartj/article/43/41/4229/6673995 (accessed January 9, 2024).